NCT06095986View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2027

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Aramchol meglumine

Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)

Trial Locations (1)

23284

The Sanyal Institute for Liver Disease & Metabolic Health at VCU, Richmond

Sponsors
All Listed Sponsors
collaborator

Virginia Commonwealth University

OTHER

lead

Galmed Pharmaceuticals Ltd

INDUSTRY

NCT06095986 - A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter